Lung cancer epidermal growth factor receptor mutations and radiotherapy response: A multicentre clinical study

Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit Rev Oncol Hematol., 19, 183, 10.1016/1040-8428(94)00144-I Harari, 2007, Biology of interactions: antiepidermal growth factor receptor agents, J Clin Oncol., 25, 4057, 10.1200/JCO.2007.11.8984 Ochs, 2004, Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors, Int J Radiat Oncol Biol Phys., 58, 941, 10.1016/j.ijrobp.2003.09.094 Tanaka, 2008, Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity, Clin Cancer Res., 14, 1266, 10.1158/1078-0432.CCR-07-1606 Liang, 2003, The epidermal growth factor receptor mediates radioresistance, Int J Radiat Oncol Biol Phys., 57, 246, 10.1016/S0360-3016(03)00511-X Wang, 2014, EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation, Cancer Res., 74, 2825, 10.1158/0008-5472.CAN-13-3157 Kavanagh, 1995, Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor, Clin Cancer Res., 1, 1557 Imai, 2013, Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor–tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation, Anticancer Res., 33, 3279 van Walraven, 2016, Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals, J Clin Epidemiol., 69, 170, 10.1016/j.jclinepi.2015.07.006 Putter, 2007, Tutorial in biostatistics: competing risks and multi-state models, Stat Med., 26, 2389, 10.1002/sim.2712 Pan, 2005, Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas, J Mol Diagn., 7, 396, 10.1016/S1525-1578(10)60569-7 Tanaka, 2015, EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma, J Thorac Oncol., 10, 1720, 10.1097/JTO.0000000000000675 Yagishita, 2015, Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer, Int J Radiat Oncol Biol Phys., 91, 140, 10.1016/j.ijrobp.2014.08.344 Lim, 2017, Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy, Clin Lung Cancer., 18, e169, 10.1016/j.cllc.2016.12.013 Mak, 2011, Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC, Oncologist., 16, 886, 10.1634/theoncologist.2011-0040 She, 2003, The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index, Clin Cancer Res., 9, 3773 Das, 2006, Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation, Cancer Res., 66, 9601, 10.1158/0008-5472.CAN-06-2627 Hirata, 2013, Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma, Anticancer Res., 33, 1649 Huang, 2011, p53 modulates acquired resistance to EGFR inhibitors and radiation, Cancer Res., 71, 7071, 10.1158/0008-5472.CAN-11-0128